trial

A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)

NCTId NCT02634346
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 403 (actual)
Sponsored by Alkermes, Inc.
Primary completion 2017-05-25
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
403 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2015-12
Primary completion
2017-05-25
Eligibility
ALL · 18 Years · 70 Years

Interventions & indications

Drugs
ALK3831Olanzapine

Sponsors

Alkermes, Inc.Lead Sponsor

Investigators

1
David McDonnell, MDStudy Director

Sites

31 total
Little Rock, United StatesSpringdale, United StatesCulver City, United StatesGarden Grove, United StatesLemon Grove, United StatesLong Beach, United StatesOrange, United StatesSan Diego, United StatesWashington D.C., United StatesNorth Miami, United StatesChicago, United StatesSt Louis, United States

Linked catalysts

1
A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENL — primary completion2017-05-25

Facts & assertions

4 sourced
Enrollment
403
Phase
PHASE3
Primary Completion Date
2017-05-25
Status
COMPLETED
relationships
The graph out of here
drug
ALK3831
drug
Olanzapine
drug
lead_sponsor
Alkermes, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
David McDonnell, MD
person